GlobalData Plc

The enteral stents market across the North American countries of Canada, Mexico, and the US is set to grow from around $46.8 million in 2016 to $62.3 million by 2023, representing a compound annual growth rate (CAGR) of 4.2%, according to GlobalData, a recognized leader in providing business information and analytics.

The company’s latest report states that the enteral stents space, which includes esophageal stents, gastrointestinal stents, and colonic stents, will primarily be driven by increased cancer rates, greater prevalence of diseases such as diabetes and obesity, and the development of stenting technology.

Brigitte Babin, MSc, Healthcare Analyst for GlobalData, explains: “The US is the largest enteral stent market globally and is expected to remain so throughout the forecast period, with an anticipated rise from $42.7 million in 2016 to around $57 million by 2023, at a CAGR of 4.2%. In terms of market segmentation, fully covered enteral stents dominate the space with a 73% share in 2016, followed by partially covered enteral stents.

“While all esophageal stents were originally uncovered, partially covered and fully covered stents have become more common, as covering helps to combat the complication of tumor and tissue ingrowth. Indeed, the fully covered and partially covered stents market segments are both increasing in North America, with a combined CAGR of 4.7% in the US, while the non-covered stents market is decreasing in all countries within the region.”

There are three key players in the international enteral stents market. Boston Scientific is the leading company in the space market thanks to an extensive product line and a presence in all segments. Its presence was further strengthened by the acquisition of EndoChoice, a former smaller player in the enteral stents market.

The other two key players in the enteral stent market are Cook Medical and Taewoong Medical. Cook Medical has established a strong presence despite a small product line, while Taewoong Medical has a more extensive product portfolio.

– Information based on GlobalData’s report: MediPoint: Enteral Stents – North America Analysis and Market Forecasts.

Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

    Press Release Healthcare

    Majority of oncology clinical trials in China failed to meet enrolment targets

    The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December 2017 failed to meet the planned enrolment targets, according to GlobalData, a leading data and analytics company. The company identified and analyzed enrollment efficiencies of 324 clinical trials during the period and found that on...

    Press Release Healthcare

    Need for supportive care in oncology will increase during the next decade

    The need for effective supportive care in oncology will increase in the next decade as patients continue to live longer and cancer progresses to become more like a chronic disease. This includes the need for chemotherapy-related conditions, as chemotherapy will remain the backbone of cancer therapy for the foreseeable future, observes GlobalData, a leading data and analytics company.

    Press Release Healthcare

    World Cancer Day: What will 2018 mean for cancer research and treatment?

    The theme of this year’s World Cancer Day held on 4th February of “We can. I can.” aimed to reinforce the public message that all individuals and groups can play their part in reducing the global burden of cancer. Indeed in recent years many events have involved collaborations between traditional drug developers, cancer treatment professionals and those of varying disciplines. Examples include the IBM Watson supercomputer which is helping physicians make treatment decisions and the development of other databases such as ASCO’s CancerLinQ which assists oncologists in monitoring and analyzing patient data.

    Press Release Healthcare

    Melanoma sales are projected to rise to $5.5bn in 2026

    The value of the melanoma market was estimated to be $3.3bn across the seven major markets (7MM*) in 2016. This is expected to grow to $5.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 5.3%, according to GlobalData, a leading data and analytics company.

    Press Release Healthcare

    Global glaucoma market to reach $3.8bn by 2026

    The total glaucoma market was estimated to be $2.6bn across the seven major markets (7MM*) in 2016. This is expected to grow to $3.8bn in 2026, at a Compound Annual Growth Rate (CAGR) of 4.1%, according to GlobalData, a leading data and analytics company.

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.

Emailpr@globaldata.com
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends… https://t.co/wJOJOqYIJF